Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2022 Clinical Practice Guideline

Nenhuma Miniatura disponível
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
AMER COLL PHYSICIANS
Autores
AWAN, Ahmed Arslan Yousuf
BERENGUER, Marina C.
BRUCHFELD, Annette
FABRIZI, Fabrizio
GOLDBERG, David S.
JIA, Jidong
KAMAR, Nassim
MOHAMED, Rosmawati
POL, Stanislas
Citação
ANNALS OF INTERNAL MEDICINE, v.176, n.12, p.1648-1655, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Description: The Kidney Disease: Improving Global Outcomes (KDIGO) 2022 clinical practice guideline on prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease (CKD) is an update of the 2018 guideline from KDIGO.Methods: The KDIGO Work Group (WG) updated the guideline, which included reviewing and grading new evidence that was identified and summarized. As in the previous guideline, the WG used the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach to appraise evidence and rate the strength of recommendations and used expert judgment to develop recommendations. New evidence led to updating of recommendations in the chapters on treatment of hepatitis C virus (HCV) infection in patients with CKD (Chapter 2), management of HCV infection before and after kidney transplant (Chapter 4), and diagnosis and management of kidney disease associated with HCV infection (Chapter 5). Recommendations in chapters on detection and evaluation of hepatitis C in CKD (Chapter 1) and prevention of HCV transmission in hemodialysis units (Chapter 3) were not updated because of an absence of significant new evidence.Recommendations: The 2022 updated guideline includes 43 graded recommendations and 20 ungraded recommendations, 7 of which are new or modified on the basis of the most recent evidence and consensus among the WG members. The updated guidelines recommend expanding treatment of hepatitis C with sofosbuvir-based regimens to patients with CKD glomerular filtration rate categories G4 and G5, including those receiving dialysis; expanding the donor pool for kidney transplant recipients by accepting HCV-positive kidneys regardless of the recipient's HCV status; and initiating direct-acting antiviral treatment of HCV-infected patients with clinical evidence of glomerulonephritis without requiring kidney biopsy. The update also addresses the use of immunosuppressive regimens in such patients.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/59195
Referências
  1. Awan AA, 2020, CLIN GASTROENTEROL H, V18, P2158, DOI 10.1016/j.cgh.2019.07.050
  2. Balk EM, 2023, KIDNEY INT REP, V8, P240, DOI 10.1016/j.ekir.2022.11.008
  3. Borgia SM, 2019, J HEPATOL, V71, P660, DOI 10.1016/j.jhep.2019.05.028
  4. Brouwers MC, 2010, CAN MED ASSOC J, V182, pE839, DOI 10.1503/cmaj.090449
  5. Daloul R, 2020, AM J TRANSPLANT, V20, P1463, DOI 10.1111/ajt.15788
  6. De Vita S, 2012, ARTHRITIS RHEUM-US, V64, P843, DOI 10.1002/art.34331
  7. Durand CM, 2018, ANN INTERN MED, V168, P533, DOI 10.7326/M17-2871
  8. European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021
  9. Goldberg DS, 2017, NEW ENGL J MED, V376, P2394, DOI 10.1056/NEJMc1705221
  10. Gordon CE, 2023, AM J KIDNEY DIS, V82, P410, DOI 10.1053/j.ajkd.2022.12.019
  11. Gordon CE, 2019, ANN INTERN MED, V171, P496, DOI 10.7326/M19-1539
  12. Gupta G, 2021, AM J TRANSPLANT, V21, P3734, DOI 10.1111/ajt.16747
  13. Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P380, DOI 10.1016/j.jclinepi.2010.09.011
  14. Jadoul M, 2022, KIDNEY INT, V102, pS129, DOI 10.1016/j.kint.2022.07.013
  15. Kasuno K, 2003, AM J KIDNEY DIS, V41, P767, DOI 10.1016/S0272-6386(03)00024-6
  16. Kirby BJ, 2015, CLIN PHARMACOKINET, V54, P677, DOI 10.1007/s40262-015-0261-7
  17. Kucirka LM, 2010, AM J TRANSPLANT, V10, P1238, DOI 10.1111/j.1600-6143.2010.03091.x
  18. Lawitz E, 2020, LANCET GASTROENTEROL, V5, P918, DOI 10.1016/S2468-1253(19)30417-0
  19. Moberg J, 2018, HEALTH RES POLICY SY, V16, DOI 10.1186/s12961-018-0320-2
  20. Nahon P, 2017, GASTROENTEROLOGY, V152, P142, DOI 10.1053/j.gastro.2016.09.009
  21. de José AP, 2021, CLIN KIDNEY J, V14, P586, DOI 10.1093/ckj/sfz178
  22. Pol S, 2017, ALIMENT PHARM THER, V46, P1054, DOI 10.1111/apt.14352
  23. Pol S, 2004, HUM PATHOL, V35, P107, DOI 10.1016/j.humpath.2003.08.012
  24. Reese PP, 2018, ANN INTERN MED, V169, P273, DOI 10.7326/M18-0749
  25. Schaubel DE, 2022, JAMA-J AM MED ASSOC, V328, P1102, DOI 10.1001/jama.2022.12868
  26. Sneller MC, 2012, ARTHRITIS RHEUM-US, V64, P835, DOI 10.1002/art.34322
  27. Terrault Norah A, 2018, Hepatology, V67, P1560, DOI [10.1002/cld.728, 10.1002/hep.29800]
  28. Torabi J, 2021, TRANSPL INFECT DIS, V23, DOI 10.1111/tid.13449
  29. Wheeler DC, 2018, KIDNEY INT SUPPL, V8, P91, DOI 10.1016/j.kisu.2018.06.001

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC